Genome Biologics develops therapies for cardiovascular and cardiometabolic diseases, utilizing AI-driven big data analysis for precision preclinical and in vivo disease models.

Genome Biologics

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

Primordial AI utilizes evolutionary data and artificial intelligence to discover drug targets, focusing on achieving next-generation drug development.

Primordial AI

Biotechnology Research

Genome Biologics | 1,261 followers on LinkedIn. Accelerated Drug Development | Genome Biologics identifies viable drug candidates and FDA approved drug repositioning compounds for Cardiovascular and Cardiometabolic disease. Capitalising on the power of our patented Artificial Intelligence (AI) driven preclinical multi-modality drug testing technology - We leverage the power of AI-based machine learning with transformative single cell in vitro and in vivo transgenesis to dramatically reduce the cost, time, and ethical burden of preclinical research in the pharmaceutical industry.

Professor at Goethe-Universität Hospital Frankfurt a. Main

Jaya Krishnan

Head of Research and Drug Discovery at Genome Biologics

Ting Yuan

🚀 Exciting News! 🚀 Genome Biologics is thrilled to announce an exclusive commercialization partnership with InSphero AG! This collaboration grants InSphero global rights to our revolutionary 3D Cardiac Organoid Platform, TrueCardium®. Together, we aim to set a new standard in cardiac disease research and therapeutic development. By combining our cutting-edge organoid technology with InSphero’s expertise, we're paving the way for faster, more accurate 𝐜𝐚𝐫𝐝𝐢𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐨𝐝𝐞𝐥𝐬. Stay tuned for more updates as we embark on this groundbreaking journey! 🌟 💡 #Innovation #Biotech #CardiacResearch #Organoids #Partnership #GenomeBiologics #InSphero

📣 BREAKING NEWS 📣 Genome Biologics are honored to be selected for this year's Startup Pitch & Partner Program at #BioVaria ! We look forward to presenting Genome Biologics and connecting with fellow enterpreneurs and broader life science community. At Genome Biologics , we are commited to disrupting and revolutionalising treatments for heart disease and tackling the larger burden of cardiovascular disease in the EU. 👉👉👉 Join us for discussions at #BioVaria and learn about our drug pipeline – with special focus on cardioinflammatory disorder - including clonal hematopoiesis of indeterminate potential (CHIP) #lifescience #cardio #drugpipeline

Metric
Company Name	Genome Biologics	DVLP	Primordial AI
Symbol
MSH ID	COM:GENOMEBIOLOGICS	COM:DVLPMEDICINES	COM:PRIMORDIALBIO
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Biotechnology
Country	US	US	US
Stage			Seed
Employee Count
Website	genomebiologics.com	dvlpmedicines.com	primordialbio.com
LinkedIn	genome-biologics	dvlpmedicines	primordial-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1	133	1.24K
Web Traffic Growth		-0.55	-0.54
Valuation
Raised Capital			4M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GENO

COM:GENOMEBIOLOGICS

Genome Biologics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue